BioInvent
Ideon Science and Technology Park
Sölvegatan 41
Lund
S-223 70
Tel: 46-46-286-8550
Fax: 46-46-211-0806
Website: http://www.bioinvent.com/
Email: info@bioinvent.com
310 articles about BioInvent
-
Notice to Annual General Meeting in BioInvent International AB - March 27, 2024
3/27/2024
The shareholders of BioInvent International AB, Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 3 May 2024 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.
-
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
3/5/2024
CASI Pharmaceuticals, Inc. and BioInvent International AB announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma in the ongoing development program in China.
-
BioInvent International AB Year-end Report January 1 - December 31, 2023
2/22/2024
BioInvent International 2023 was a landmark year for BioInvent with positive clinical readouts from three Phase 1/2 programs.
-
Invitation to Presentation of BioInvent’s Year-end Report 2023
2/20/2024
BioInvent International AB invites investors, analysts, and the press to a presentation of the year-end report 2023 at 2:00 pm on February 22.
-
BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence
2/9/2024
BioInvent International AB announced a clinical supply agreement with AstraZeneca to evaluate BioInvent's anti-FcyRIIB antibody, BI-1206, in combination with rituximab and Calquence®, in a Phase 1/2a study in non-Hodgkin's lymphoma.
-
BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
1/12/2024
BioInvent International AB announced that its early discovery partner Exelixis, Inc. has provided a notice of termination for the option and license agreement for novel antibodies for use in immuno-oncology therapeutics.
-
BioInvent Announces 2024 Strategic Priorities and Anticipated Milestones
1/4/2024
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, highlighted the Company's strategic priorities and anticipated milestones for 2024.
-
BioInvent Enrolls First Patient in Phase 1/2a Clinical Trial with TNFR2 Antibody BI-1910
12/5/2023
BioInvent International AB today announces it has enrolled the first patient in its Phase 1/2a trial of the monoclonal antibody BI-1910, the company's second anti-tumor necrosis factor receptor 2 (TNFR2) program to enter clinical development.
-
BioInvent Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607
12/5/2023
BioInvent International today presents the first clinical data from a Phase 1/2a trial of its second FcyRIIB-blocking antibody BI-1607.
-
BioInvent presents preclinical data at SITC providing clear evidence of the potential of anti-TNFR2 antibody BI-1910
10/31/2023
BioInvent will present preclinical data on its anti-tumor necrosis factor receptor 2 (TNFR2) agonistic antibody BI-1910 at the Society of Immunotherapy for Cancer (SITC) 38th Annual Meeting in San Diego, California.
-
BioInvent International AB: Interim report January–September 2023
10/26/2023
In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study.
-
Invitation to Presentation of BioInvent’s Interim Report January - September 2023
10/25/2023
BioInvent International invites investors, analysts and the press to a presentation of the interim report January- September 2023 at 2:00 pm on Thursday October 26. The report will be published at 8:00 am CET the same day. BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When:
-
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)
10/10/2023
Transgene and BioInvent International AB announce that the first patient of the Phase I part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA® has been dosed.
-
BioInvent and Transgene: First patient treated in Part B of Phase 1 trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA® (pembrolizumab)
10/10/2023
BioInvent International AB and Transgene announce that that the first patient of the Phase 1 part B clinical trial evaluating the combination of BT-001 and MSD's anti-PD-1 therapy, KEYTRUDA® has been dosed.
-
BioInvent to Hold Two Poster Presentations at SITC 38th Annual Meeting
9/27/2023
BioInvent International announces it will hold two poster presentations on its anti-tumor necrosis factor receptor 2 programs at the Society of Immunotherapy for Cancer 38th Annual Meeting, held November 3-5, 2023, in San Diego, California.
-
BioInvent recruits first patient in Phase 2a trial of single agent BI-1808 for the treatment of advanced malignancies
9/22/2023
BioInvent International AB announces recruitment of the first patient in the single agent Phase 2a part of its Phase 1/2a trial of its first-in-class anti-TNFR2 antibody BI-1808 in advanced malignancies.
-
BioInvent initiates subcutaneous arm of Phase 1/2 trial with BI-1206 in solid tumors
9/8/2023
BioInvent International AB announces the enrollment of the first patient in a Phase 1/2 trial in combination with KEYTRUDA®, MSD's anti-PD-1 therapy, investigating a subcutaneous formulation of its lead drug candidate, the novel anti-FcyRIIB antibody BI-1206, in solid tumors.
-
BioInvent International AB: Interim report January-June 2023
8/30/2023
BioInvent International "In the quarter, we had impressive early signals of efficacy in the Phase 1/2 trial of our lead drug candidate, the novel anti-FcgRIIB antibody BI-1206, in combination with rituximab in non-Hodgkin's lymphoma.
-
BioInvent Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with anti-TNFR2 Antibody BI-1808 in Advanced Malignancies
6/21/2023
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces strong interim safety data from its Phase 1/2a trial of its first-in-class anti-TNFR2 antibody BI-1808 in advanced malignancies.
-
BioInvent Announces Abstract Presentation of BI-1206 at the 17th International Conference of Malignant Lymphoma 2023
6/13/2023
BioInvent International Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the study design and status, and summarizes the early clinical results generated so far in the dose escalation phase.